Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

BACKGROUND: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles; therefore, costs for managing adverse eve...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Mickisch, G, Gore, M, Escudier, B, Procopio, G, Walzer, S, Nuijten, M
Formáid: Artigo
Teanga:Inglês
Foilsithe: Nature Publishing Group 2010
Ábhair:
Clinical Study
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2813739/
https://ncbi.nlm.nih.gov/pubmed/19920817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605417
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla